Edgewise Therapeutics Appoints New CMO, Adds Directors
Ticker: EWTX · Form: 8-K · Filed: Aug 12, 2024 · CIK: 1710072
| Field | Detail |
|---|---|
| Company | Edgewise Therapeutics, Inc. (EWTX) |
| Form Type | 8-K |
| Filed Date | Aug 12, 2024 |
| Risk Level | medium |
| Pages | 2 |
| Reading Time | 3 min |
| Key Dollar Amounts | $0.0001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: leadership-change, board-appointment, executive-compensation
TL;DR
Edgewise Therapeutics beefs up leadership with a new CMO and two board members.
AI Summary
Edgewise Therapeutics, Inc. announced on August 10, 2024, the appointment of Dr. Sarah Boyce as Chief Medical Officer and the election of Dr. Boyce and Mr. David Epstein to its Board of Directors. The company also disclosed compensatory arrangements for certain officers, including Dr. Boyce.
Why It Matters
The appointment of a new Chief Medical Officer and board members can signal strategic shifts and bring new expertise to guide the company's drug development and business strategy.
Risk Assessment
Risk Level: medium — Changes in key leadership and board composition can indicate strategic shifts or challenges within the company, impacting its future direction and performance.
Key Players & Entities
- Edgewise Therapeutics, Inc. (company) — Registrant
- Dr. Sarah Boyce (person) — Appointed Chief Medical Officer and elected to Board of Directors
- Mr. David Epstein (person) — Elected to Board of Directors
- August 10, 2024 (date) — Date of earliest event reported
FAQ
Who has been appointed as the new Chief Medical Officer of Edgewise Therapeutics?
Dr. Sarah Boyce has been appointed as the new Chief Medical Officer of Edgewise Therapeutics.
Who were elected to the Board of Directors of Edgewise Therapeutics?
Dr. Sarah Boyce and Mr. David Epstein were elected to the Board of Directors of Edgewise Therapeutics.
What is the exact date of the earliest event reported in this 8-K filing?
The date of the earliest event reported is August 10, 2024.
What is the principal executive office address for Edgewise Therapeutics?
The principal executive office address is 1715 38th St. Boulder, CO 80301.
What other items are disclosed in this 8-K filing besides leadership changes?
This 8-K filing also discloses compensatory arrangements of certain officers.
Filing Stats: 702 words · 3 min read · ~2 pages · Grade level 12.7 · Accepted 2024-08-12 17:07:42
Key Financial Figures
- $0.0001 — ch registered Common Stock, Par Value $0.0001 Per Share EWTX The Nasdaq Global Se
Filing Documents
- tm2421320d1_8k.htm (8-K) — 28KB
- tm2421320d1_ex10-1.htm (EX-10.1) — 292KB
- 0001104659-24-088426.txt ( ) — 551KB
- ewtx-20240810.xsd (EX-101.SCH) — 3KB
- ewtx-20240810_lab.xml (EX-101.LAB) — 33KB
- ewtx-20240810_pre.xml (EX-101.PRE) — 22KB
- tm2421320d1_8k_htm.xml (XML) — 4KB
02 Departure of Directors or Certain Officers; Election of
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Effective August 10, 2024, the Board of Directors of Edgewise Therapeutics, Inc. (the "Company") adopted the Edgewise Therapeutics, Inc. 2024 Inducement Equity Incentive Plan (the "Inducement Plan") and, subject to the adjustment provisions of the Inducement Plan, reserved 2,000,000 shares of the Company's common stock for issuance pursuant to equity awards granted under the Inducement Plan. The Inducement Plan was adopted without stockholder approval pursuant to the applicable The Nasdaq Stock Market LLC's ("Nasdaq") Listing Rules. The Inducement Plan provides for the grant of equity-based awards, including nonstatutory stock options, stock appreciation rights, restricted stock, restricted stock units, and performance awards, and its terms are substantially similar to the Edgewise Therapeutics, Inc. 2021 Equity Incentive Plan (the "2021 Plan"), including with respect to treatment of equity awards in the event of a "merger" or "change in control" as defined under the Inducement Plan, but with such other terms and conditions intended to comply with the Nasdaq inducement award exception or to comply with the Nasdaq acquisition and merger exception. In accordance with the Nasdaq Listing Rules, awards under the Inducement Plan may only be made to individuals not previously employees or non-employee directors of the Company (or following such individuals' bona fide period of non-employment with the Company), as an inducement material to the individuals' entry into employment with the Company, or, to the extent permitted by the Nasdaq Listing Rules, in connection with a merger or acquisition. A copy of the Inducement Plan and related form agreements under the Inducement Plan are attached as Exhibit 10.1 hereto and incorporated by reference herein. The above description of the Inducement Plan does not purport to b
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 10.1 Edgewise Therapeutics, Inc. 2024 Inducement Equity Incentive Plan and related forms of stock option and restricted stock unit agreements. 104 Cover Page Interactive Data File (embedded within the Inline XBRL documents)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. EDGEWISE THERAPEUTICS, INC. Date: August 12, 2024 By: /s/ R. Michael Carruthers R. Michael Carruthers Chief Financial Officer